Brokerages Expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post $0.97 EPS

Analysts expect that Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) will post earnings per share of $0.97 for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Collegium Pharmaceutical’s earnings, with the highest EPS estimate coming in at $1.03 and the lowest estimate coming in at $0.82. Collegium Pharmaceutical reported earnings of $0.41 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 136.6%. The firm is scheduled to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Collegium Pharmaceutical will report full year earnings of $5.61 per share for the current year, with EPS estimates ranging from $4.75 to $6.32. For the next fiscal year, analysts forecast that the firm will report earnings of $7.44 per share, with EPS estimates ranging from $6.56 to $8.97. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Collegium Pharmaceutical.

Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) last released its quarterly earnings results on Thursday, February 24th. The specialty pharmaceutical company reported ($0.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($1.59). The firm had revenue of $27.36 million for the quarter, compared to analysts’ expectations of $80.75 million. Collegium Pharmaceutical had a net margin of 25.83% and a return on equity of 4.07%.

A number of equities research analysts have recently commented on COLL shares. Piper Sandler upped their target price on shares of Collegium Pharmaceutical from $36.00 to $42.00 and gave the company an “overweight” rating in a report on Tuesday, February 22nd. TheStreet cut shares of Collegium Pharmaceutical from a “b-” rating to a “c+” rating in a report on Monday, April 11th. HC Wainwright increased their price target on shares of Collegium Pharmaceutical from $26.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday, February 15th. Needham & Company LLC upped their target price on shares of Collegium Pharmaceutical from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, April 6th. Finally, Cantor Fitzgerald upgraded shares of Collegium Pharmaceutical from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $18.00 to $26.00 in a research report on Tuesday, February 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $31.00.

In other news, EVP Scott Dreyer sold 10,559 shares of the firm’s stock in a transaction on Friday, February 18th. The shares were sold at an average price of $21.61, for a total value of $228,179.99. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 5.18% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its stake in Collegium Pharmaceutical by 344.3% in the second quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock valued at $74,000 after acquiring an additional 2,410 shares during the last quarter. SG Americas Securities LLC acquired a new position in Collegium Pharmaceutical during the 3rd quarter worth about $765,000. Victory Capital Management Inc. lifted its position in Collegium Pharmaceutical by 9.9% during the 3rd quarter. Victory Capital Management Inc. now owns 111,920 shares of the specialty pharmaceutical company’s stock valued at $2,209,000 after purchasing an additional 10,036 shares during the period. LSV Asset Management bought a new stake in Collegium Pharmaceutical during the 3rd quarter worth approximately $2,899,000. Finally, Swiss National Bank grew its stake in shares of Collegium Pharmaceutical by 1.7% during the 3rd quarter. Swiss National Bank now owns 70,100 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after acquiring an additional 1,200 shares in the last quarter.

Collegium Pharmaceutical has a 1 year low of $15.90 and a 1 year high of $25.66. The stock has a market capitalization of $551.59 million, a PE ratio of 9.53, a PEG ratio of 0.16 and a beta of 0.96. The company has a current ratio of 1.13, a quick ratio of 1.07 and a debt-to-equity ratio of 0.99. The company has a fifty day moving average of $18.90 and a two-hundred day moving average of $19.03.

Collegium Pharmaceutical Company Profile (Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

See Also